Signal transduction pathways and transcription factors triggered by arsenic trioxide in leukemia cells

Toxicology and Applied Pharmacology

Volumn 244, Issue 3, 2010, Pages 385-392

  Sumi, Daigo ^a   Shinkai, Yasuhiro ^b   Kumagai, Yoshito ^b  

^a TOKUSHIMA BUNRI UNIVERSITY   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Arsenic trioxide; Reactive oxygen species; Signal transduction; Transcription factor

Indexed keywords

APOPTOSIS SIGNAL REGULATING KINASE 1; ARSENIC TRIOXIDE; GLUTATHIONE PEROXIDASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P53; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; THIOREDOXIN REDUCTASE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR SP1; XANTHINE; XANTHINE OXIDASE; ORGANOARSENIC DERIVATIVE; OXIDE;

DRUG EXPOSURE; DRUG MECHANISM; ELECTRON TRANSPORT; ENZYME ACTIVITY; HUMAN; LEUKEMIA CELL; LEUKEMIA REMISSION; MITOCHONDRION; MOLECULAR MECHANICS; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PROMYELOCYTIC LEUKEMIA; PROTEIN DEGRADATION; REVIEW; SIGNAL TRANSDUCTION; APOPTOSIS; DRUG EFFECT; METABOLISM;

APOPTOSIS; ARSENICALS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; OXIDES; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 77950480769     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2010.02.012     Document Type: Review

References (104)

1. Abate C., Patel L., Rauscher F.J., Curran T. Redox regulation of fos and jun DNA-binding activity in vitro. Science 1990, 249:1157-1161.
2. Achanta G., Huang P. Role of p53 in sensing oxidative DNA damage in response to reactive oxygen species-generating agents. Cancer Res. 2004, 64:6233-6239.
3. Aposhian H.V., Gurzau E.S., Le X.C., Gurzau A., Healy S.M., Lu X., Ma M., Yip L., Zakharyan R.A., Maiorino R.M., Dart R.C., Tircus M.G., Gonzalez-Ramirez D., Morgan D.L., Avram D., Aposhian M.M. Occurrence of monomethylarsonous acid in urine of humans exposed to inorganic arsenic. Chem. Res. Toxicol. 2000, 13:693-697.
4. 2- in vascular smooth muscle cells. Circ. Res. 1995, 77:29-36.
5. Barchowsky A., Dudek E.J., Treadwell M.D., Wetterhahn K.E. Arsenic induces oxidant stress and NF-kappa B activation in cultured aortic endothelial cells. Free Radic. Biol. Med. 1996, 21:783-790.
6. Barchowsky A., Roussel R.R., Klei L.R., James P.E., Ganju N., Smith K.R., Dudek E.J. Low levels of arsenic trioxide stimulate proliferative signals in primary vascular cells without activating stress effector pathways. Toxicol. Appl. Pharmacol. 1999, 159:65-75.
7. Bargou R.C., Leng C., Krappmann D., Emmerich F., Mapara M.Y., Bommert K., Royer H.D., Scheidereit C., Dorken B. High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood 1996, 87:4340-4347.
8. Bargou R.C., Emmerich F., Krappmann D., Bommert K., Mapara M.Y., Arnold W., Royer H.D., Grinstein E., Greiner A., Scheidereit C., Dorken B. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J. Clin. Invest. 1997, 100:2961-2969.
9. Borrow J., Goddard A.D., Sheer D., Solomon E. Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. Science 1990, 249:1577-1580.
10. Brandes R.P., Kreuzer J. Vascular NADPH oxidases: molecular mechanisms of activation. Cardiovasc. Res. 2005, 65:16-27.
11. Cavigelli M., Li W.W., Lin A., Su B., Yoshioka K., Karin M. The tumor promoter arsenite stimulates AP-1 activity by inhibiting a JNK phosphatase. EMBO J. 1996, 15:6269-6279.
12. Chen C.J., Hsueh Y.M., Lai M.S., Shyu M.P., Chen S.Y., Wu M.M., Kuo T.L., Tai T.Y. Increased prevalence of hypertension and long-term arsenic exposure. Hypertension 1995, 25:53-60.
13. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 1996, 88:1052-1061.
14. 3 exerts dose-dependent dual effects on APL cells. Blood 1997, 89:3345-3353.
15. Chou W.C., Hawkins A.L., Barrett J.F., Griffin C.A., Dang C.V. Arsenic inhibition of telomerase transcription leads to genetic instability. J. Clin. Invest. 2001, 108:1541-1547.
16. Chou W.C., Jie C., Kenedy A.A., Jones R.J., Trush M.A., Dang C.V. Role of NADPH oxidase in arsenic-induced reactive oxygen species formation and cytotoxicity in myeloid leukemia cells. Proc. Natl. Acad. Sci. USA 2004, 101:4578-4583.
17. Chou W.C., Chen H.Y., Yu S.L., Cheng L., Yang P.C., Dang C.V. Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood 2005, 106:304-310.
18. Chouchane S., Snow E.T. In vitro effect of arsenical compounds on glutathione-related enzymes. Chem. Res. Toxicol. 2001, 14:517-522.
19. Colotta F., Polentarutti N., Sironi M., Mantovani A. Expression and involvement of c-fos and c-jun protooncogenes in programmed cell death induced by growth factor deprivation in lymphoid cell lines. J. Biol. Chem. 1992, 267:18278-18283.
20. Datta R., Yoshinaga K., Kaneki M., Pandey P., Kufe D. Phorbol ester-induced generation of reactive oxygen species is protein kinase cbeta-dependent and required for SAPK activation. J. Biol. Chem. 2000, 275:41000-41003.
21. Davison K., Mann K.K., Waxman S., Miller W.H. JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells. Blood 2004, 103:3496-3502.
22. de The H., Chomienne C., Lanotte M., Degos L., Dejean A. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature 1990, 347:558-561.
23. Duyndam M.C., Hulscher S.T., van der Wall E., Pinedo H.M., Boven E. Evidence for a role of p38 kinase in hypoxia-inducible factor 1-independent induction of vascular endothelial growth factor expression by sodium arsenite. J. Biol. Chem. 2003, 278:6885-6895.
24. Engel R.R., Hopenhayn-Rich C., Receveur O., Smith A.H. Vascular effects of chronic arsenic exposure: a review. Epidemiol. Rev. 1994, 16:184-209.
25. Felix K., Manna S.K., Wise K., Barr J., Ramesh G.T. Low levels of arsenite activates nuclear factor-kappaB and activator protein-1 in immortalized mesencephalic cells. J. Biochem. Mol. Toxicol. 2005, 19:67-77.
26. Filippova M., Duerksen-Hughes P.J. Inorganic and dimethylated arsenic species induce cellular p53. Chem. Res. Toxicol. 2003, 16:423-431.
27. Flohe L., Brigelius-Flohe R., Saliou C., Traber M.G., Packer L. Redox regulation of NF-kappa B activation. Free Radic. Biol. Med. 1997, 22:1115-1126.
28. Franke T.F., Kaplan D.R., Cantley L.C. PI3K: downstream AKTion blocks apoptosis. Cell 1997, 88:435-437.
29. Fujino G., Noguchi T., Takeda K., Ichijo H. Thioredoxin and protein kinases in redox signaling. Semin. Cancer Biol. 2006, 16:427-435.
30. Fujisawa S., Ohno R., Shigeno K., Sahara N., Nakamura S., Naito K., Kobayashi M., Shinjo K., Takeshita A., Suzuki Y., Hashimoto H., Kinoshita K., Shimoya M., Kaise T., Ohnishi K. Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxide. Cancer Chemother. Pharmacol. 2007, 59:485-493.
31. Goddard A.D., Borrow J., Freemont P.S., Solomon E. Characterization of a zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia. Science 1991, 254:1371-1374.
32. Hai T., Curran T. Cross-family dimerization of transcription factors Fos/Jun and ATF/CREB alters DNA binding specificity. Proc. Natl. Acad. Sci. USA 1991, 88:3720-3724.
33. Ham J., Babij C., Whitfield J., Pfarr C.M., Lallemand D., Yaniv M., Rubin L.L. A c-Jun dominant negative mutant protects sympathetic neurons against programmed cell death. Neuron 1995, 14:927-939.
34. Hayakawa T., Kobayashi Y., Cui X., Hirano S. A new metabolic pathway of arsenite: arsenic-glutathione complexes are substrates for human arsenic methyltransferase Cyt19. Arch. Toxicol. 2005, 79:183-191.
35. Hayden M.S., Ghosh S. Signaling to NF-kappaB. Genes Dev. 2004, 18:2195-2224.
36. Healy S.M., Wildfang E., Zakharyan R.A., Aposhian H.V. Diversity of inorganic arsenite biotransformation. Biol. Trace Elem. Res. 1999, 68:249-266.
37. Hille R., Stewart R.C., Fee J.A., Massey V. The interaction of arsenite with xanthine oxidase. J. Biol. Chem. 1983, 258:4849-4856.
38. Holmgren A., Bjornstedt M. Thioredoxin and thioredoxin reductase. Methods Enzymol. 1995, 252:199-208.
39. Ichijo H., Nishida E., Irie K., ten Dijke P., Saitoh M., Moriguchi T., Takagi M., Matsumoto K., Miyazono K., Gotoh Y. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. Science 1997, 275:90-94.
40. 2+-dependent production of superoxide. Int. J. Cancer 2001, 92:518-526.
41. Jing Y., Dai J., Chalmers-Redman R.M., Tatton W.G., Waxman S. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 1999, 94:2102-2111.
42. Joe Y., Jeong J.H., Yang S., Kang H., Motoyama N., Pandolfi P.P., Chung J.H., Kim M.K. ATR, PML, and CHK2 play a role in arsenic trioxide-induced apoptosis. J. Biol. Chem. 2006, 281:28764-28771.
43. Kadono T., Inaoka T., Murayama N., Ushijima K., Nagano M., Nakamura S., Watanabe C., Tamaki K., Ohtsuka R. Skin manifestations of arsenicosis in two villages in Bangladesh. Int. J. Dermatol. 2002, 41:841-846.
44. Kajiguchi T., Yamamoto K., Hossain K., Akhand A.A., Nakashima I., Naoe T., Saito H., Emi N. Sustained activation of c-jun-terminal kinase (JNK) is closely related to arsenic trioxide-induced apoptosis in an acute myeloid leukemia (M2)-derived cell line, NKM-1. Leukemia 2003, 17:2189-2195.
45. Kang Y.H., Lee S.J. The role of p38 MAPK and JNK in arsenic trioxide-induced mitochondrial cell death in human cervical cancer cells. J. Cell. Physiol. 2008, 217:23-33.
46. Kapahi P., Takahashi T., Natoli G., Adams S.R., Chen Y., Tsien R.Y., Karin M. Inhibition of NF-kappa B activation by arsenite through reaction with a critical cysteine in the activation loop of Ikappa B kinase. J. Biol. Chem. 2000, 275:36062-36066.
47. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006, 441:431-436.
48. Karin M., Greten F.R. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol. 2005, 5:749-759.
49. Lagerkvist B.E., Linderholm H., Nordberg G.F. Arsenic and Raynaud's phenomenon. Vasospastic tendency and excretion of arsenic in smelter workers before and after the summer vacation. Int. Arch. Occup. Environ. Health 1988, 60:361-364.
50. Le X.C., Lu X., Ma M., Cullen W.R., Aposhian H.V., Zheng B. Speciation of key arsenic metabolic intermediates in human urine. Anal. Chem. 2000, 72:5172-5177.
51. Le X.C., Ma M., Cullen W.R., Aposhian H.V., Lu X., Zheng B. Determination of monomethylarsonous acid, a key arsenic methylation intermediate, in human urine. Environ. Health Perspect. 2000, 108:1015-1018.
52. Lee J.H., Jeong M.W., Kim W., Choi Y.H., Kim K.T. Cooperative roles of c-Abl and Cdk5 in regulation of p53 in response to oxidative stress. J. Biol. Chem. 2008, 283:19826-19835.
53. Lemarie A., Morzadec C., Merino D., Micheau O., Fardel O., Vernhet L. Arsenic trioxide induces apoptosis of human monocytes during macrophagic differentiation through nuclear factor-kappaB-related survival pathway down-regulation. J. Pharmacol. Exp. Ther. 2006, 316:304-314.
54. Li L., Wang J., Ye R.D., Shi G., Jin H., Tang X., Yi J. PML/RARalpha fusion protein mediates the unique sensitivity to arsenic cytotoxicity in acute promyelocytic leukemia cells: mechanisms involve the impairment of cAMP signaling and the aberrant regulation of NADPH oxidase. J. Cell. Physiol. 2008, 217:486-493.
55. Lin S., Del Razo L.M., Styblo M., Wang C., Cullen W.R., Thomas D.J. Arsenicals inhibit thioredoxin reductase in cultured rat hepatocytes. Chem. Res. Toxicol. 2001, 14:305-311.
56. Liu Y., Guyton K.Z., Gorospe M., Xu Q., Lee J.C., Holbrook N.J. Differential activation of ERK, JNK/SAPK and P38/CSBP/RK map kinase family members during the cellular response to arsenite. Free Radic. Biol. Med. 1996, 21:771-781.
57. Liu L., Trimarchi J.R., Navarro P., Blasco M.A., Keefe D.L. Oxidative stress contributes to arsenic-induced telomere attrition, chromosome instability, and apoptosis. J. Biol. Chem. 2003, 278:31998-32004.
58. Liu Q., Hilsenbeck S., Gazitt Y. Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL. Blood 2003, 101:4078-4087.
59. Liu B., Chen Y., St Clair D.K. ROS and p53: a versatile partnership. Free Radic. Biol. Med. 2008, 44:1529-1535.
60. Lu J., Chew E.H., Holmgren A. Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc. Natl. Acad. Sci. USA 2007, 104:12288-12293.
61. Lunghi P., Tabilio A., Lo-Coco F., Pelicci P.G., Bonati A. Arsenic trioxide (ATO) and MEK1 inhibition synergize to induce apoptosis in acute promyelocytic leukemia cells. Leukemia 2005, 19:234-244.
62. Lunghi P., Giuliani N., Mazzera L., Lombardi G., Ricca M., Corradi A., Cantoni A.M., Salvatore L., Riccioni R., Costanzo A., Testa U., Levrero M., Rizzoli V., Bonati A. Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways. Blood 2008, 112:2450-2462.
63. Lynn S., Gurr J.R., Lai H.T., Jan K.Y. NADH oxidase activation is involved in arsenite-induced oxidative DNA damage in human vascular smooth muscle cells. Circ. Res. 2000, 86:514-519.
64. Maeda H., Hori S., Nishitoh H., Ichijo H., Ogawa O., Kakehi Y., Kakizuka A. Tumor growth inhibition by arsenic trioxide (As2O3) in the orthotopic metastasis model of androgen-independent prostate cancer. Cancer Res. 2001, 61:5432-5440.
65. Mandal B.K., Ogra Y., Suzuki K.T. Identification of dimethylarsinous and monomethylarsonous acids in human urine of the arsenic-affected areas in West Bengal, India. Chem. Res. Toxicol. 2001, 14:371-378.
66. Mathas S., Lietz A., Janz M., Hinz M., Jundt F., Scheidereit C., Bommert K., Dorken B. Inhibition of NF-kappaB essentially contributes to arsenic-induced apoptosis. Blood 2003, 102:1028-1034.
67. McCubrey J.A., Lahair M.M., Franklin R.A. Reactive oxygen species-induced activation of the MAP kinase signaling pathways. Antioxid. Redox Signal. 2006, 8:1775-1789.
68. Muller J.M., Rupec R.A., Baeuerle P.A. Study of gene regulation by NF-kappa B and AP-1 in response to reactive oxygen intermediates. Methods 1997, 11:301-312.
69. Musti A.M., Treier M., Bohmann D. Reduced ubiquitin-dependent degradation of c-Jun after phosphorylation by MAP kinases. Science 1997, 275:400-402.
70. Nauseef W.M. Biological roles for the NOX family NADPH oxidases. J. Biol. Chem. 2008, 283:16961-16965.
71. Pantano C., Reynaert N.L., van der Vliet A., Janssen-Heininger Y.M. Redox-sensitive kinases of the nuclear factor-kappaB signaling pathway. Antioxid. Redox Signal. 2006, 8:1791-1806.
72. 3) inhibits invasion of HT1080 human fibrosarcoma cells: role of nuclear factor-kappaB and reactive oxygen species. J. Cell. Biochem. 2005, 95:955-969.
73. Partridge M.A., Huang S.X., Hernandez-Rosa E., Davidson M.M., Hei T.K. Arsenic induced mitochondrial DNA damage and altered mitochondrial oxidative function: implications for genotoxic mechanisms in mammalian cells. Cancer Res. 2007, 67:5239-5247.
74. Pelicano H., Feng L., Zhou Y., Carew J.S., Hileman E.O., Plunkett W., Keating M.J., Huang P. Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J. Biol. Chem. 2003, 278:37832-37839.
75. Peng Z., Peng L., Fan Y., Zandi E., Shertzer H.G., Xia Y. A critical role for IkappaB kinase beta in metallothionein-1 expression and protection against arsenic toxicity. J. Biol. Chem. 2007, 282:21487-21496.
76. Pi J., Kumagai Y., Sun G., Yamauchi H., Yoshida T., Iso H., Endo A., Yu L., Yuki K., Miyauchi T., Shimojo N. Decreased serum concentrations of nitric oxide metabolites among Chinese in an endemic area of chronic arsenic poisoning in inner Mongolia. Free Radic. Biol. Med. 2000, 28:1137-1142.
77. Pi J., Yamauchi H., Kumagai Y., Sun G., Yoshida T., Aikawa H., Hopenhayn-Rich C., Shimojo N. Evidence for induction of oxidative stress caused by chronic exposure of Chinese residents to arsenic contained in drinking water. Environ. Health Perspect. 2002, 110:331-336.
78. Ramos A.M., Fernandez C., Amran D., Sancho P., de Blas E., Aller P. Pharmacologic inhibitors of PI3K/Akt potentiate the apoptotic action of the antileukemic drug arsenic trioxide via glutathione depletion and increased peroxide accumulation in myeloid leukemia cells. Blood 2005, 105:4013-4020.
79. Riley T., Sontag E., Chen P., Levine A. Transcriptional control of human p53-regulated genes. Nat. Rev. Mol. Cell Biol. 2008, 9:402-412.
80. Roussel R.R., Barchowsky A. Arsenic inhibits NF-kappaB-mediated gene transcription by blocking IkappaB kinase activity and IkappaBalpha phosphorylation and degradation. Arch. Biochem. Biophys. 2000, 377:204-212.
81. Safe S., Abdelrahim M. Sp transcription factor family and its role in cancer. Eur. J. Cancer 2005, 41:2438-2448.
82. Salazar A.M., Ostrosky-Wegman P., Menendez D., Miranda E., Garcia-Carranca A., Rojas E. Induction of p53 protein expression by sodium arsenite. Mutat. Res. 1997, 381:259-265.
83. Schreck R., Rieber P., Baeuerle P.A. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. EMBO J. 1991, 10:2247-2258.
84. Shen S.C., Yang L.Y., Lin H.Y., Wu C.Y., Su T.H., Chen Y.C. Reactive oxygen species-dependent HSP90 protein cleavage participates in arsenical As(+3)- and MMA(+3)-induced apoptosis through inhibition of telomerase activity via JNK activation. Toxicol. Appl. Pharmacol. 2008, 229:239-251.
85. Shumilla J.A., Wetterhahn K.E., Barchowsky A. Inhibition of NF-kappa B binding to DNA by chromium, cadmium, mercury, zinc, and arsenite in vitro: evidence of a thiol mechanism. Arch. Biochem. Biophys. 1998, 349:356-362.
86. Smith K.R., Klei L.R., Barchowsky A. Arsenite stimulates plasma membrane NADPH oxidase in vascular endothelial cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 2001, 280:L442-L449.
87. Soignet S.L., Maslak P., Wang Z.G., Jhanwar S., Calleja E., Dardashti L.J., Corso D., DeBlasio A., Gabrilove J., Scheinberg D.A., Pandolfi P.P., Warrell R.P. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N. Engl. J. Med. 1998, 339:1341-1348.
88. Sumimoto H. Structure, regulation and evolution of Nox-family NADPH oxidases that produce reactive oxygen species. FEBS J. 2008, 275:3249-3277.
89. Sun Y., Oberley L.W. Redox regulation of transcriptional activators. Free Radic. Biol. Med. 1996, 21:335-348.
90. Tabellini G., Cappellini A., Tazzari P.L., Fala F., Billi A.M., Manzoli L., Cocco L., Martelli A.M. Phosphoinositide 3-kinase/Akt involvement in arsenic trioxide resistance of human leukemia cells. J. Cell. Physiol. 2005, 202:623-634.
91. Tabellini G., Tazzari P.L., Bortul R., Evangelisti C., Billi A.M., Grafone T., Martinelli G., Baccarani M., Martelli A.M. Phosphoinositide 3-kinase/Akt inhibition increases arsenic trioxide-induced apoptosis of acute promyelocytic and T-cell leukaemias. Br. J. Haematol. 2005, 130:716-725.
92. Tobiume K., Matsuzawa A., Takahashi T., Nishitoh H., Morita K., Takeda K., Minowa O., Miyazono K., Noda T., Ichijo H. ASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis. EMBO Rep. 2001, 2:222-228.
93. Torres M. Mitogen-activated protein kinase pathways in redox signaling. Front. Biosci. 2003, 8:d369-d391.
94. Tournier C., Hess P., Yang D.D., Xu J., Turner T.K., Nimnual A., Bar-Sagi D., Jones S.N., Flavell R.A., Davis R.J. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science 2000, 288:870-874.
95. Tseng W.P., Chu H.M., How S.W., Fong J.M., Lin C.S., Yeh S. Prevalence of skin cancer in an endemic area of chronic arsenicism in Taiwan. J. Natl. Cancer Inst. 1968, 40:453-463.
96. Verma A., Mohindru M., Deb D.K., Sassano A., Kambhampati S., Ravandi F., Minucci S., Kalvakolanu D.V., Platanias L.C. Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to arsenic trioxide. J. Biol. Chem. 2002, 277:44988-44995.
97. Vivanco I., Sawyers C.L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer 2002, 2:489-501.
98. Wang J., Li L., Cang H., Shi G., Yi J. NADPH oxidase-derived reactive oxygen species are responsible for the high susceptibility to arsenic cytotoxicity in acute promyelocytic leukemia cells. Leuk. Res. 2008, 32:429-436.
99. Webster K.A., Prentice H., Bishopric N.H. Oxidation of zinc finger transcription factors: physiological consequences. Antioxid. Redox Signal. 2001, 3:535-548.
100. Wijeweera J.B., Gandolfi A.J., Parrish A., Lantz R.C. Sodium arsenite enhances AP-1 and NFkappaB DNA binding and induces stress protein expression in precision-cut rat lung slices. Toxicol. Sci. 2001, 61:283-294.
101. Yan W., Arai A., Aoki M., Ichijo H., Miura O. ASK1 is activated by arsenic trioxide in leukemic cells through accumulation of reactive oxygen species and may play a negative role in induction of apoptosis. Biochem. Biophys. Res. Commun. 2007, 355:1038-1044.
102. Yeo M., Rha S.Y., Jeung H.C., Hu S.X., Yang S.H., Kim Y.S., An S.W., Chung H.C. Attenuation of telomerase activity by hammerhead ribozyme targeting human telomerase RNA induces growth retardation and apoptosis in human breast tumor cells. Int. J. Cancer 2005, 114:484-489.
103. Yoda A., Toyoshima K., Watanabe Y., Onishi N., Hazaka Y., Tsukuda Y., Tsukada J., Kondo T., Tanaka Y., Minami Y. Arsenic trioxide augments Chk2/p53-mediated apoptosis by inhibiting oncogenic Wip1 phosphatase. J. Biol. Chem. 2008, 283:18969-18979.
104. Zhang Y., Cao E.H., Qin J.F. Up-regulation of telomere-binding TRF1, TRF2 related to reactive oxygen species induced by As(2)O(3) in MGC-803 cells. Eur. J. Pharmacol. 2005, 516:1-9.